SOURCE: Goldman Small Cap Research, Inc.

April 22, 2013 09:00 ET

Goldman Small Cap Research Provides Valuation for Nuvilex, Inc.'s Medical Marijuana Segment

BALTIMORE, MD--(Marketwired - Apr 22, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has released a research report which highlights the valuation for the medical marijuana segment of Nuvilex, Inc. (OTCQB: NVLX). Nuvilex is an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.

Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., builds upon the Company's many years of experience in developing "all-natural" products for various uses by studying the medical applications of marijuana (Cannabis sativa) and developing treatments for serious human diseases. The use of Cannabis for medicinal purposes dates back more than 3,000 years. The components of marijuana that have shown medical activity are broadly known as "cannabinoids." Approximately 70 cannabinoids have been found in Cannabis sativa.

In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.

"In a number of studies, cannabinoids have demonstrated an ability to act as an anticancer agent. Leveraging the use of the Company's successful encapsulation technology to treat certain cancers in clinical trials and other tests, the initial efforts of Medical Marijuana Sciences, Inc. are targeted towards developing treatments for some of the most difficult-to-treat forms of cancer."

"We proffer that given management's deep experience in the development of clinical trials of ethical drugs, delivery systems, and live-cell encapsulation, Nuvilex will emerge as the de-facto oncology treatment leader in medical marijuana. Not only does this play to the Company's strengths, but the field is less crowded than the pain relief segment. As a result, we believe that the Company's medical marijuana initiatives should be afforded a market value akin to the industry average of roughly $70M."

To view a summary of the report or download the report in its entirety, please visit

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit:

Contact Information